T1	CHEM 9 18	sirolimus
#1	AnnotatorNotes T1	C0072980; sirolimus; Organic Chemical · Antibiotic
T2	DISO 36 73	síndrome nefrótico córtico-resistente
#2	AnnotatorNotes T2	C0403397; Steroid-resistant nephrotic syndrome; Disease or Syndrome
T3	DISO 106 127	proteinuria nefrótica
#3	AnnotatorNotes T3	C0445118; Nephrotic range proteinuria; Finding
T4	DISO 160 179	insuficiencia renal
#4	AnnotatorNotes T4	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T5	PROC 200 221	protocolo terapéutico
#5	AnnotatorNotes T5	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T6	CHEM 226 235	sirolimus
#6	AnnotatorNotes T6	C0072980; sirolimus; Organic Chemical · Antibiotic
T7	PROC 281 344	estudio clínico prospectivo, intervencionista y no aleatorizado
#7	AnnotatorNotes T7	C3274035; Interventional Study; Research Activity + C0033522; Prospective Studies; Research Activity + C2985410; Nonrandomized; Research Activity
T8	DISO 421 458	síndrome nefrótico córtico-resistente
#8	AnnotatorNotes T8	C0403397; Steroid-resistant nephrotic syndrome; Disease or Syndrome
T9	DISO 470 508	glomerulosclerosis focal y segmentaria
#9	AnnotatorNotes T9	C0017668; Focal glomerulosclerosis; Disease or Syndrome
T10	CHEM 535 549	ciclofosfamida
#10	AnnotatorNotes T10	C0010583; cyclophosphamide; Organic Chemical · Pharmacologic Substance
T11	CHEM 557 587	inhibidores de la calcineurina
#11	AnnotatorNotes T11	C1562036; Calcineurin inhibitor; Pharmacologic Substance
T12	CHEM 603 612	enalapril
#12	AnnotatorNotes T12	C0014025; enalapril; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T13	CHEM 615 623	losartán
#13	AnnotatorNotes T13	C0126174; losartan; Organic Chemical · Pharmacologic Substance
T14	CHEM 653 662	sirolimus
#14	AnnotatorNotes T14	C0072980; sirolimus; Organic Chemical · Antibiotic
T15	PROC 689 700	tratamiento
#15	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	PROC 717 750	Evaluamos la eficacia terapéutica
#16	AnnotatorNotes T16	C1707887; Efficacy Study; Research Activity
T17	DISO 779 790	proteinuria
#17	AnnotatorNotes T17	C0033687; Proteinuria; Finding
T18	DISO 873 889	daño histológico
#18	AnnotatorNotes T18	C0010957; Tissue damage; Injury or Poisoning (?)
T19	CHEM 954 963	sirolimus
#19	AnnotatorNotes T19	C0072980; sirolimus; Organic Chemical · Antibiotic
T20	DISO 1033 1051	síndrome nefrótico
#20	AnnotatorNotes T20	C0027726; Nephrotic Syndrome; Disease or Syndrome
T21	DISO 1110 1126	daño histológico
#21	AnnotatorNotes T21	C0010957; Tissue damage; Injury or Poisoning (?)
T22	CHEM 1184 1193	sirolimus
#22	AnnotatorNotes T22	C0072980; sirolimus; Organic Chemical · Antibiotic
T23	PROC 1218 1229	tratamiento
#23	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	DISO 1253 1290	síndrome nefrótico córtico-resistente
#24	AnnotatorNotes T24	C0403397; Steroid-resistant nephrotic syndrome; Disease or Syndrome
T25	ANAT 174 179	renal
#25	AnnotatorNotes T25	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T26	LIVB 22 31	pacientes
#26	AnnotatorNotes T26	C0030705; Patients; Patient or Disabled Group
T27	LIVB 254 263	pacientes
#27	AnnotatorNotes T27	C0030705; Patients; Patient or Disabled Group
T29	LIVB 356 363	cohorte
#28	AnnotatorNotes T29	C0599755; Cohort; Population Group
T30	LIVB 370 379	pacientes
#29	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T31	Age 402 409	10 años
T33	Dose 670 679	3,6 mg/m2
T34	Duration 706 714	12 meses
T36	LIVB 985 994	pacientes
#30	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	LIVB 1239 1248	pacientes
#31	AnnotatorNotes T37	C0030705; Patients; Patient or Disabled Group
T28	Frequency 679 683	/día
T32	Observation 510 521	resistentes
#32	AnnotatorNotes T32	C3542449; Drug Resistance Status; Finding
R1	Experiences Arg1:T26 Arg2:T2	
R2	Experiences Arg1:T26 Arg2:T1	
T35	Quantifier_or_Qualifier 74 82	primario
#33	AnnotatorNotes T35	C0205225; Primary; Qualitative Concept
R3	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T35	
T38	Observation 140 150	progresión
#34	AnnotatorNotes T38	C1457868; Worse; Finding
R4	Causes Arg1:T3 Arg2:T38	
R5	Before Arg1:T3 Arg2:T4	
R6	Location_of Arg1:T25 Arg2:T4	
R7	Used_for Arg1:T6 Arg2:T5	
R8	Experiences Arg1:T27 Arg2:T6	
T39	Neg_cue 329 331	no
T40	Quantifier_or_Qualifier 332 344	aleatorizado
A1	Assertion T40 Negated
R9	Negation Arg1:T39 Arg2:T40	
R10	Has_Quantifier_or_Qualifier Arg1:T7 Arg2:T40	
R11	Has_Age Arg1:T30 Arg2:T31	
R12	Has_Age Arg1:T29 Arg2:T31	
T41	Quantifier_or_Qualifier 459 467	primario
#35	AnnotatorNotes T41	C0205225; Primary; Qualitative Concept
R13	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T41	
R14	Experiences Arg1:T29 Arg2:T6	
R15	Experiences Arg1:T30 Arg2:T6	
R16	Has_Age Arg1:T27 Arg2:T31	
R17	Experiences Arg1:T27 Arg2:T8	
R18	Experiences Arg1:T27 Arg2:T9	
R19	Experiences Arg1:T27 Arg2:T32	
R20	Experiences Arg1:T27 Arg2:T10	
R21	Experiences Arg1:T27 Arg2:T11	
R22	Experiences Arg1:T27 Arg2:T12	
R23	Experiences Arg1:T27 Arg2:T13	
R24	Experiences Arg1:T29 Arg2:T8	
R25	Experiences Arg1:T29 Arg2:T9	
R26	Experiences Arg1:T29 Arg2:T32	
R27	Experiences Arg1:T29 Arg2:T10	
R28	Experiences Arg1:T29 Arg2:T11	
R29	Experiences Arg1:T29 Arg2:T12	
R30	Experiences Arg1:T29 Arg2:T13	
R31	Experiences Arg1:T30 Arg2:T8	
R32	Experiences Arg1:T30 Arg2:T9	
R33	Experiences Arg1:T30 Arg2:T32	
R34	Experiences Arg1:T30 Arg2:T10	
R35	Experiences Arg1:T30 Arg2:T11	
R36	Experiences Arg1:T30 Arg2:T12	
R37	Experiences Arg1:T30 Arg2:T13	
R38	Overlap Arg1:T8 Arg2:T9	
R39	Overlap Arg1:T32 Arg2:T10	
R40	Overlap Arg1:T32 Arg2:T11	
R41	Overlap Arg1:T32 Arg2:T12	
R42	Overlap Arg1:T32 Arg2:T13	
R43	Has_Dose_or_Strength Arg1:T14 Arg2:T33	
R44	Has_Frequency Arg1:T14 Arg2:T28	
R45	Used_for Arg1:T14 Arg2:T15	
R46	Has_Duration_or_Interval Arg1:T14 Arg2:T34	
T42	Observation 792 807	respuesta total
T43	Observation 792 801;809 816	respuesta parcial
#36	AnnotatorNotes T43	C1521726; partial response; Finding
T44	Observation 792 801;819 826	respuesta ausente
#37	AnnotatorNotes T44	C0438286; Absent response to treatment; Finding
T45	Date 890 904	pretratamiento
R47	Overlap Arg1:T18 Arg2:T45	
R48	Overlap Arg1:T17 Arg2:T43	
R49	Overlap Arg1:T17 Arg2:T44	
R50	Overlap Arg1:T17 Arg2:T42	
T46	CONC 910 916	tiempo
#38	AnnotatorNotes T46	C0040223; Time; Temporal Concept
R51	Before Arg1:T46 Arg2:T19	
T47	Observation 1004 1020	remisión parcial
#39	AnnotatorNotes T47	C1521726; partial response; Finding
T48	Observation 1004 1012;1023 1028	remisión total
R52	Before Arg1:T18 Arg2:T42	
R53	Before Arg1:T18 Arg2:T44	
R54	Before Arg1:T18 Arg2:T43	
R58	Experiences Arg1:T36 Arg2:T47	
R57	Experiences Arg1:T36 Arg2:T48	
R59	Before Arg1:T20 Arg2:T48	
R60	Before Arg1:T20 Arg2:T47	
R61	Before Arg1:T21 Arg2:T48	
R62	Before Arg1:T21 Arg2:T47	
R63	Used_for Arg1:T22 Arg2:T23	
R64	Experiences Arg1:T37 Arg2:T22	
R65	Experiences Arg1:T37 Arg2:T24	
T49	Spec_cue 1299 1312	probablemente
T50	CONC 1330 1348	inicio terapéutico
A2	Assertion T50 Speculated
R66	Speculation Arg1:T49 Arg2:T50	
T51	Quantifier_or_Qualifier 1349 1359	más precoz
A3	Assertion T51 Speculated
R67	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T51	
R68	Overlap Arg1:T8 Arg2:T32	
R69	Overlap Arg1:T9 Arg2:T32	
R70	Overlap Arg1:T17 Arg2:T18	
R71	Overlap Arg1:T20 Arg2:T21	
#40	AnnotatorNotes T42	C1275810; Complete therapeutic response; Finding
#41	AnnotatorNotes T48	C1275810; Complete therapeutic response; Finding (?)
T53	Observation 1152 1161	respuesta
#43	AnnotatorNotes T53	C1319171; Medication response; Finding
R72	Experiences Arg1:T36 Arg2:T53	
#42	AnnotatorNotes T45	C1882440; Pre-Therapy; Temporal Concept | C3539075; Pretreatment Period; Temporal Concept
A4	Experiencer T26 Patient
A5	Experiencer T27 Patient
A6	Experiencer T29 Patient
A7	Experiencer T30 Patient
A8	Experiencer T36 Patient
A9	Experiencer T37 Patient
